GT Biopharma (GTBP) Retained Earnings (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Retained Earnings of -$726.8 million for Q1 2026, down 204.58% year-over-year from $695.0 million in Q1 2025, and down 199.61% quarter-over-quarter from $729.7 million in Q4 2025.
GT Biopharma (GTBP) Retained Earnings (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Retained Earnings for 17 consecutive years, with -$726.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 204.58% year-over-year to -$726.8 million; the TTM figure through Mar 2026 stood at -$726.8 million (down 204.58% YoY), while the FY2025 annual figure was $729.7 million, up 5.21% from the prior year.
- Retained Earnings eased to -$726.8 million in Q1 2026 per GTBP's latest filing, from $729.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $729.7 million in Q4 2025 and bottomed at -$726.8 million in Q1 2026.
- Historically, Retained Earnings has averaged $173.9 million across 5 years, with a median of $685.5 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 207.78% — and 2026, when it tumbled 204.58%.
- GT Biopharma's Retained Earnings stood at $686.2 million in 2022, then sank by 199.4% to -$682.1 million in 2023, then surged by 201.68% to $693.6 million in 2024, then advanced by 5.21% to $729.7 million in 2025, then plunged by 199.61% to -$726.8 million in 2026.
- Business Quant data shows GTBP's Retained Earnings at -$726.8 million in Q1 2026, $729.7 million in Q4 2025, and -$718.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | 734.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -726.84 Mn |
| Dec 31, 2025 | 729.66 Mn |
| Sep 30, 2025 | -718.10 Mn |
| Jun 30, 2025 | 700.38 Mn |
| Mar 31, 2025 | 695.02 Mn |
| Dec 31, 2024 | 693.55 Mn |
| Sep 30, 2024 | -691.45 Mn |
| Mar 31, 2024 | 689.64 Mn |
| Dec 31, 2023 | -682.07 Mn |
| Sep 30, 2023 | 689.07 Mn |
| Jun 30, 2023 | 688.41 Mn |
| Mar 31, 2023 | -674.70 Mn |
| Dec 31, 2022 | 686.17 Mn |
| Sep 30, 2022 | 684.80 Mn |
| Jun 30, 2022 | 677.41 Mn |
| Mar 31, 2022 | -659.02 Mn |
| Dec 31, 2021 | 674.35 Mn |
| Sep 30, 2021 | -635.39 Mn |
| Jun 30, 2021 | 655.66 Mn |
| Mar 31, 2021 | -625.08 Mn |